Change is a-coming. Thats what Rino Rappouli (of Novartis Vaccines and Diagnostics in Siena, Italy) and Antonio Cassone (of the Department of Infectious, Parasitic and Immunomediated Diseases at the Istituto Superiore di Sanita Rome) argue in a new Perspectives piece accepted for the inaugural issue of mBio: the days of single pathogen- or single disease-targeted vaccines are on the wane, in part because when a number of vaccines are used separately, their acceptability to the public decreases. Universal vaccines offer one promising way to move forward. Genomics informs us about commonalities and conserved antigens among pathogens that we can use to develop universal vaccines to target even phylogenetically-distant pathogens.
A preliminary version of the paper is available on the mBio website, and a final, typeset version of the article will appear in the inaugural issue of the online journal in May.
A preliminary version of the paper is available on the mBio website, and a final, typeset version of the article will appear in the inaugural issue of the online journal in May.
